Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and pharmacokinetics of IQNLF in healthy adults
NL-OMON20298Recruiting
- Sponsor
- IQ Therapeutics
- Start
- Feb 2011
- Countries
- 1
01
Overview
Trial in inhalational anthrax (2 arms), sponsored by IQ Therapeutics. Primary endpoint: Safety and tolerability. Started Feb 2011; status: recruiting.
02
Conditions
inhalational anthrax
Beyond the preview
Go deeper on NL-OMON20298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20298.